MX2021015270A - Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb. - Google Patents
Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb.Info
- Publication number
- MX2021015270A MX2021015270A MX2021015270A MX2021015270A MX2021015270A MX 2021015270 A MX2021015270 A MX 2021015270A MX 2021015270 A MX2021015270 A MX 2021015270A MX 2021015270 A MX2021015270 A MX 2021015270A MX 2021015270 A MX2021015270 A MX 2021015270A
- Authority
- MX
- Mexico
- Prior art keywords
- binding molecules
- bispecific antigen
- muc16
- bind
- combination
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 7
- 102000036639 antigens Human genes 0.000 title abstract 7
- 108091007433 antigens Proteins 0.000 title abstract 7
- 102000007269 CA-125 Antigen Human genes 0.000 abstract 3
- 108010008629 CA-125 Antigen Proteins 0.000 abstract 3
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 102000055862 human MUC16 Human genes 0.000 abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 230000006052 T cell proliferation Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computed tomography [CT]
- A61B6/037—Emission tomography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
- A61B6/48—Diagnostic techniques
- A61B6/481—Diagnostic techniques involving the use of contrast agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
- A61K51/1039—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors
- A61K51/1042—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants against T-cell receptors against T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- High Energy & Nuclear Physics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente descripción métodos de tratamiento del cáncer mediante el uso de moléculas biespecíficas de unión a antígeno que se unen a mucina 16 (MUC16) y a CD3. De acuerdo con determinadas modalidades, los anticuerpos útiles en la presente descripción se unen a MUC16 humana con alta afinidad y se unen a CD3 para inducir la proliferación de linfocitos T humanos. De acuerdo con determinadas modalidades, las moléculas biespecíficas de unión a antígeno que comprenden un primer dominio de unión a antígeno que se une específicamente a CD3 humano, y una segunda molécula de unión a antígeno que se une específicamente a MUC16 humana son particularmente útiles en la presente descripción. En determinadas modalidades, las moléculas biespecíficas de unión a antígeno en combinación con un agonista anti-4-1BB son capaces de inhibir el crecimiento de tumores que expresan MUC16, por ejemplo, tumores de ovarios. Las moléculas biespecíficas de unión a antígeno en combinación con un agonista anti-4-1BB son útiles para el tratamiento de enfermedades y trastornos en los que se desea una respuesta inmunitaria dirigida regulada positivamente o inducida y/o terapéuticamente beneficiosa, por ejemplo, en el tratamiento de varios cánceres.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962864960P | 2019-06-21 | 2019-06-21 | |
PCT/US2020/038669 WO2020257604A1 (en) | 2019-06-21 | 2020-06-19 | Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021015270A true MX2021015270A (es) | 2022-01-18 |
Family
ID=71842848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021015270A MX2021015270A (es) | 2019-06-21 | 2020-06-19 | Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200399371A1 (es) |
EP (1) | EP3986934A1 (es) |
JP (1) | JP2022537269A (es) |
KR (1) | KR20220024035A (es) |
CN (1) | CN113993547B (es) |
AU (1) | AU2020294790A1 (es) |
CA (1) | CA3140083A1 (es) |
IL (1) | IL288916A (es) |
MA (1) | MA56537A (es) |
MX (1) | MX2021015270A (es) |
WO (1) | WO2020257604A1 (es) |
ZA (1) | ZA202108895B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023177772A1 (en) * | 2022-03-17 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating recurrent epithelioid sarcoma with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA2103059C (en) | 1991-06-14 | 2005-03-22 | Paul J. Carter | Method for making humanized antibodies |
US5428156A (en) | 1993-04-02 | 1995-06-27 | Associated Universities, Inc. | Synthesis of macrocyclic polyaminocarboxylates and their use for preparing stable radiometal antibody immunoconjugates for therapy, spect and pet imaging |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
EP2445936A1 (en) | 2009-06-26 | 2012-05-02 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
PT2505654T (pt) | 2010-02-08 | 2016-11-18 | Regeneron Pharma | Rato de cadeia leve comum |
TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
WO2015140212A1 (en) | 2014-03-19 | 2015-09-24 | Universität Zürich | Multidentate bifunctional chelating agents for radionuclide complexation in diagnostics and therapy |
SI3515487T1 (sl) * | 2016-09-23 | 2023-09-29 | Regeneron Pharmaceuticals, Inc. | Bispecifična protitelesa proti-MUC16-CD3 in konjugati zdravil proti-MUC16 |
PL3559034T3 (pl) * | 2016-12-20 | 2021-04-19 | F. Hoffmann-La Roche Ag | Terapia skojarzona dwuswoistymi przeciwciałami anty-CD20/anty-CD3 i agonistami 4-1BB (CD137) |
-
2020
- 2020-06-19 EP EP20747267.1A patent/EP3986934A1/en active Pending
- 2020-06-19 CN CN202080045426.2A patent/CN113993547B/zh active Active
- 2020-06-19 AU AU2020294790A patent/AU2020294790A1/en active Pending
- 2020-06-19 JP JP2021573213A patent/JP2022537269A/ja active Pending
- 2020-06-19 MA MA056537A patent/MA56537A/fr unknown
- 2020-06-19 MX MX2021015270A patent/MX2021015270A/es unknown
- 2020-06-19 KR KR1020217040895A patent/KR20220024035A/ko unknown
- 2020-06-19 CA CA3140083A patent/CA3140083A1/en active Pending
- 2020-06-19 WO PCT/US2020/038669 patent/WO2020257604A1/en active Application Filing
- 2020-06-19 US US16/906,634 patent/US20200399371A1/en active Pending
-
2021
- 2021-11-10 ZA ZA2021/08895A patent/ZA202108895B/en unknown
- 2021-12-12 IL IL288916A patent/IL288916A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN113993547B (zh) | 2024-04-26 |
US20200399371A1 (en) | 2020-12-24 |
IL288916A (en) | 2022-02-01 |
ZA202108895B (en) | 2023-03-29 |
AU2020294790A1 (en) | 2021-12-16 |
CN113993547A (zh) | 2022-01-28 |
EP3986934A1 (en) | 2022-04-27 |
CA3140083A1 (en) | 2020-12-24 |
WO2020257604A1 (en) | 2020-12-24 |
KR20220024035A (ko) | 2022-03-03 |
MA56537A (fr) | 2022-04-27 |
JP2022537269A (ja) | 2022-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
PH12019500604A1 (en) | Anti-muc16 (mucin 16) antibodies | |
PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
PH12019500603A1 (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
MY195059A (en) | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof | |
PH12021550031A1 (en) | BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF | |
MX2021007497A (es) | Anticuerpos biespecificos anti-cd28 x anti-cd22 y usos de estos. | |
MX2019006955A (es) | Terapia de combinacion con agonistas de 4-1bb orientados (cd137). | |
EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
MX2020004410A (es) | Anticuerpos biespecificos con funciones efectoras reducidas. | |
PH12020551689A1 (en) | Her2-targeting antigen binding molecules comprising 4-1bbl | |
MX2021015270A (es) | Uso de moleculas biespecificas de union a antigeno que se unen a muc16 y cd3 en combinacion con la estimulacion conjunta de 4-1bb. | |
MX2021015271A (es) | Uso de moleculas biespecificas de union a antigeno que se unen a psma y cd3 en combinacion con la estimulacion conjunta de 4-1bb. | |
PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
EA202191677A1 (ru) | Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения | |
EA202190314A1 (ru) | Биспецифические анти-bcma x анти-cd3 антитела и способы их применения | |
EA202190089A1 (ru) | Биспецифичные антитела анти-psma x анти-cd28 и их применения | |
EA201990779A1 (ru) | Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство | |
EA202090303A3 (ru) | Композиции антител для лечения опухолей |